Solitary pulmonary nodule evaluation of solitary pulmonary nodule
|
Pulmonary Nodule Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Solitary pulmonary nodule evaluation of solitary pulmonary nodule On the Web |
|
American Roentgen Ray Society Images of Solitary pulmonary nodule evaluation of solitary pulmonary nodule |
|
FDA on Solitary pulmonary nodule evaluation of solitary pulmonary nodule |
|
CDC on Solitary pulmonary nodule evaluation of solitary pulmonary nodule |
|
Solitary pulmonary nodule evaluation of solitary pulmonary nodule in the news |
|
Blogs on Solitary pulmonary nodule evaluation of solitary pulmonary nodule |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]
Overview
A hallmark feature in the evaluation of solitary pulmonary nodule is the malignancy risk assessment. The evaluation approach of solitary pulmonary nodule will mainly depend in the initial morphological evaluation of the nodule (size, margins, contours, and growth). Other characteristics, such as: location, clinical features, and distribution may be helpful for the risk assessment, therapeutical management, surveillance, and follow-up of solitary pulmonary nodule. Solitary pulmonary nodule can be divided into 4 risk categories: low risk, intermediate, moderate and high risk. Based upon these risk categories, complementary diagnostic studies and management, include: PET/CT scan, CT scan, non-surgical biopsy, and surgical resection.